An 11-year review of levetiracetam ingestions in children less than 6 years of age

J. C. Lewis, Timothy E Albertson, M. J. Walsh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background. Levetiracetam is a new anticonvulsant, which works to block high-voltage-activated Ca++ channels in children, for partial-onset seizures. Reports of clinical experience with pediatric ingestions are minimal. The purpose of this study was to characterize the toxicity of accidental levetiracetam exposures in children less than 6 years of age.

Methods. This was an 11-year retrospective observational case series of pediatric (< 6 years old) levetiracetam ingestions reported to a Poison Control System from 2002 to 2013. Case narratives were individually reviewed to collect desired information on exposure and clinical course. Inclusion criteria were levetiracetam as a single ingested medication, age less than 6 years, treatment in a health care facility, and followed to a known outcome.

Results. Eighty-two cases met inclusion criteria with 55% female patients and overall median age of 2.0 years (range: 1-60 months). The levetiracetam dose ingested was reported in 69 (84.1%) cases, with exact dose (median dose, 45.0 mg/kg; range, 10.5-1429 mg/kg) reported in 33 cases (40.2%). Of these, twenty-nine cases (88%) involved the oral solution formulation and 28 cases (85%) had unintentional therapeutic error as the cause of the exposure. No dose-response relationship was demonstrated; however, the odds of a levetiracetam-naive patient, (median dose, 26.9 mg/kg; N = 15) with an unintentional exposure, developing drowsiness or ataxia was 6 times that of a patient who was not naïve to levetiracetam (median dose, 70.1 mg/kg; N = 20) (Odds ratio [OR], 6.0; 95% confidence interval [CI], 1.03-35.91).Of the 82 cases, 17 (20.7%) developed untoward clinical effects of drowsiness and/or ataxia. Eighty patients (97.6%) were treated and discharged from the emergency department, and two patients (2.4%) were admitted. The two patients admitted included a two-month old who was accidentally given a dose 10 times that of her usual dose and a 3-year old who was lethargic on arrival to the hospital after ingestion of an unknown dose. Of all patients, 66 patients (80.5%) had no effect from the drug exposure. The medical outcome was considered to be minor in 15 cases (18.3%), and moderate in 1 case (1.2%). There were no cases with major outcomes and no deaths.

Conclusions. Pediatric levetiracetam exposures were associated with few transient clinical effects. Poison Control Centers may wish to consider acuity of ingestion when developing send-in protocols.

Original languageEnglish (US)
Pages (from-to)964-968
Number of pages5
JournalClinical Toxicology
Volume52
Issue number9
DOIs
StatePublished - Nov 1 2014

Fingerprint

etiracetam
Eating
Pediatrics
Sleep Stages
Poisons
Ataxia
Poison Control Centers
Health Facilities
Health care

Keywords

  • Anticonvulsant
  • CNS/Psychological
  • Complications of poisoning
  • Organ/tissue
  • Other
  • Pharmaceuticals
  • Specific

ASJC Scopus subject areas

  • Toxicology
  • Medicine(all)

Cite this

An 11-year review of levetiracetam ingestions in children less than 6 years of age. / Lewis, J. C.; Albertson, Timothy E; Walsh, M. J.

In: Clinical Toxicology, Vol. 52, No. 9, 01.11.2014, p. 964-968.

Research output: Contribution to journalArticle

@article{66c259d91326407d9e6a6f4d518e82bb,
title = "An 11-year review of levetiracetam ingestions in children less than 6 years of age",
abstract = "Background. Levetiracetam is a new anticonvulsant, which works to block high-voltage-activated Ca++ channels in children, for partial-onset seizures. Reports of clinical experience with pediatric ingestions are minimal. The purpose of this study was to characterize the toxicity of accidental levetiracetam exposures in children less than 6 years of age.Methods. This was an 11-year retrospective observational case series of pediatric (< 6 years old) levetiracetam ingestions reported to a Poison Control System from 2002 to 2013. Case narratives were individually reviewed to collect desired information on exposure and clinical course. Inclusion criteria were levetiracetam as a single ingested medication, age less than 6 years, treatment in a health care facility, and followed to a known outcome.Results. Eighty-two cases met inclusion criteria with 55{\%} female patients and overall median age of 2.0 years (range: 1-60 months). The levetiracetam dose ingested was reported in 69 (84.1{\%}) cases, with exact dose (median dose, 45.0 mg/kg; range, 10.5-1429 mg/kg) reported in 33 cases (40.2{\%}). Of these, twenty-nine cases (88{\%}) involved the oral solution formulation and 28 cases (85{\%}) had unintentional therapeutic error as the cause of the exposure. No dose-response relationship was demonstrated; however, the odds of a levetiracetam-naive patient, (median dose, 26.9 mg/kg; N = 15) with an unintentional exposure, developing drowsiness or ataxia was 6 times that of a patient who was not na{\"i}ve to levetiracetam (median dose, 70.1 mg/kg; N = 20) (Odds ratio [OR], 6.0; 95{\%} confidence interval [CI], 1.03-35.91).Of the 82 cases, 17 (20.7{\%}) developed untoward clinical effects of drowsiness and/or ataxia. Eighty patients (97.6{\%}) were treated and discharged from the emergency department, and two patients (2.4{\%}) were admitted. The two patients admitted included a two-month old who was accidentally given a dose 10 times that of her usual dose and a 3-year old who was lethargic on arrival to the hospital after ingestion of an unknown dose. Of all patients, 66 patients (80.5{\%}) had no effect from the drug exposure. The medical outcome was considered to be minor in 15 cases (18.3{\%}), and moderate in 1 case (1.2{\%}). There were no cases with major outcomes and no deaths.Conclusions. Pediatric levetiracetam exposures were associated with few transient clinical effects. Poison Control Centers may wish to consider acuity of ingestion when developing send-in protocols.",
keywords = "Anticonvulsant, CNS/Psychological, Complications of poisoning, Organ/tissue, Other, Pharmaceuticals, Specific",
author = "Lewis, {J. C.} and Albertson, {Timothy E} and Walsh, {M. J.}",
year = "2014",
month = "11",
day = "1",
doi = "10.3109/15563650.2014.965828",
language = "English (US)",
volume = "52",
pages = "964--968",
journal = "Clinical Toxicology",
issn = "1556-3650",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - An 11-year review of levetiracetam ingestions in children less than 6 years of age

AU - Lewis, J. C.

AU - Albertson, Timothy E

AU - Walsh, M. J.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Background. Levetiracetam is a new anticonvulsant, which works to block high-voltage-activated Ca++ channels in children, for partial-onset seizures. Reports of clinical experience with pediatric ingestions are minimal. The purpose of this study was to characterize the toxicity of accidental levetiracetam exposures in children less than 6 years of age.Methods. This was an 11-year retrospective observational case series of pediatric (< 6 years old) levetiracetam ingestions reported to a Poison Control System from 2002 to 2013. Case narratives were individually reviewed to collect desired information on exposure and clinical course. Inclusion criteria were levetiracetam as a single ingested medication, age less than 6 years, treatment in a health care facility, and followed to a known outcome.Results. Eighty-two cases met inclusion criteria with 55% female patients and overall median age of 2.0 years (range: 1-60 months). The levetiracetam dose ingested was reported in 69 (84.1%) cases, with exact dose (median dose, 45.0 mg/kg; range, 10.5-1429 mg/kg) reported in 33 cases (40.2%). Of these, twenty-nine cases (88%) involved the oral solution formulation and 28 cases (85%) had unintentional therapeutic error as the cause of the exposure. No dose-response relationship was demonstrated; however, the odds of a levetiracetam-naive patient, (median dose, 26.9 mg/kg; N = 15) with an unintentional exposure, developing drowsiness or ataxia was 6 times that of a patient who was not naïve to levetiracetam (median dose, 70.1 mg/kg; N = 20) (Odds ratio [OR], 6.0; 95% confidence interval [CI], 1.03-35.91).Of the 82 cases, 17 (20.7%) developed untoward clinical effects of drowsiness and/or ataxia. Eighty patients (97.6%) were treated and discharged from the emergency department, and two patients (2.4%) were admitted. The two patients admitted included a two-month old who was accidentally given a dose 10 times that of her usual dose and a 3-year old who was lethargic on arrival to the hospital after ingestion of an unknown dose. Of all patients, 66 patients (80.5%) had no effect from the drug exposure. The medical outcome was considered to be minor in 15 cases (18.3%), and moderate in 1 case (1.2%). There were no cases with major outcomes and no deaths.Conclusions. Pediatric levetiracetam exposures were associated with few transient clinical effects. Poison Control Centers may wish to consider acuity of ingestion when developing send-in protocols.

AB - Background. Levetiracetam is a new anticonvulsant, which works to block high-voltage-activated Ca++ channels in children, for partial-onset seizures. Reports of clinical experience with pediatric ingestions are minimal. The purpose of this study was to characterize the toxicity of accidental levetiracetam exposures in children less than 6 years of age.Methods. This was an 11-year retrospective observational case series of pediatric (< 6 years old) levetiracetam ingestions reported to a Poison Control System from 2002 to 2013. Case narratives were individually reviewed to collect desired information on exposure and clinical course. Inclusion criteria were levetiracetam as a single ingested medication, age less than 6 years, treatment in a health care facility, and followed to a known outcome.Results. Eighty-two cases met inclusion criteria with 55% female patients and overall median age of 2.0 years (range: 1-60 months). The levetiracetam dose ingested was reported in 69 (84.1%) cases, with exact dose (median dose, 45.0 mg/kg; range, 10.5-1429 mg/kg) reported in 33 cases (40.2%). Of these, twenty-nine cases (88%) involved the oral solution formulation and 28 cases (85%) had unintentional therapeutic error as the cause of the exposure. No dose-response relationship was demonstrated; however, the odds of a levetiracetam-naive patient, (median dose, 26.9 mg/kg; N = 15) with an unintentional exposure, developing drowsiness or ataxia was 6 times that of a patient who was not naïve to levetiracetam (median dose, 70.1 mg/kg; N = 20) (Odds ratio [OR], 6.0; 95% confidence interval [CI], 1.03-35.91).Of the 82 cases, 17 (20.7%) developed untoward clinical effects of drowsiness and/or ataxia. Eighty patients (97.6%) were treated and discharged from the emergency department, and two patients (2.4%) were admitted. The two patients admitted included a two-month old who was accidentally given a dose 10 times that of her usual dose and a 3-year old who was lethargic on arrival to the hospital after ingestion of an unknown dose. Of all patients, 66 patients (80.5%) had no effect from the drug exposure. The medical outcome was considered to be minor in 15 cases (18.3%), and moderate in 1 case (1.2%). There were no cases with major outcomes and no deaths.Conclusions. Pediatric levetiracetam exposures were associated with few transient clinical effects. Poison Control Centers may wish to consider acuity of ingestion when developing send-in protocols.

KW - Anticonvulsant

KW - CNS/Psychological

KW - Complications of poisoning

KW - Organ/tissue

KW - Other

KW - Pharmaceuticals

KW - Specific

UR - http://www.scopus.com/inward/record.url?scp=84910045776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910045776&partnerID=8YFLogxK

U2 - 10.3109/15563650.2014.965828

DO - 10.3109/15563650.2014.965828

M3 - Article

VL - 52

SP - 964

EP - 968

JO - Clinical Toxicology

JF - Clinical Toxicology

SN - 1556-3650

IS - 9

ER -